myriocin
Den här sidan gäller myriocin. När flera former ingår i en ingrediensgrupp har varje form egna källor och forskningskopplingar.
Sidan är delvis färdig
Här finns forskningsunderlag. Läs källorna och vilket underlag varje avsnitt bygger på.
Vi saknar ännu en genomgång av grundbeskrivning, användning och begränsningar.
Sidan ger ingen samlad bedömning av nytta eller säkerhet, eller råd om dosering och behandling.
Vad är myriocin?
En lättläst grundbeskrivning är ännu inte klar för den här formen. Se källans namn och kemiska uppgifter i kemisk fördjupning.
Användning · genomgång saknas ännu
Vi har ännu ingen källgranskad genomgång av användningen för den här formen. Produkter där ämnet har deklarerats finns längre ner på sidan.
Att ett ämne förekommer i en produkt eller har en viss roll i kroppen visar inte i sig vilken effekt ett tillskott har.
Vad säger forskningen?
Här finns 2 forskningssammanställningar kopplade till den här ämnesposten. Läs vilken form och vilka deltagare som undersöktes innan du tolkar resultatet.
Urvalet består av artikelutdrag. Det är ännu ingen samlad bedömning av ingrediensens effekter.
Här kan du läsa sammanställningar från utvalda delar av forskningsartiklar. En enskild studie visar en del av bilden och ger inte i sig råd om att använda ett tillskott.
Intratracheal myriocin enhances allergen-induced Th2 inflammation and airway hyper-responsiveness. ↗
Edukulla R, Rehn KL, Liu B, McAlees JW, Hershey GK, Wang YH, Lewkowich I, Lindsley AW.
Vad undersöktes?
- Hur undersöktes det?
- Utilizing myriocin, a potent inhibitor of sphingolipid synthesis, we evaluated the immune regulatory role of de novo ceramide generation in vitro and in vivo.
- Vilka undersöktes?
- BALB/C mice
- Vilken ämnesform?
- intratracheal myriocin
- Vilken mängd användes?
- 1.2 μg/intratracheal dose
- Hur länge pågick studien?
- serially immunized intratracheally every 48 h for 2 weeks
Studieuppgifterna återges som originalcitat. Uppgifter som saknas här kan finnas i originalutdraget.
Vad kom studien fram till?
Författarna rapporterar att intratrakealt myriocin hämmade SPT-aktivitet och minskade ceramidnivåer i lungvävnad hos möss. Enbart myriocin gav ingen signifikant ökning av luftvägshyperreaktivitet, medan samtidig behandling med HDM och myriocin förstärkte HDM-inducerad luftvägshyperreaktivitet och inflammation i musmodellen.
Vad behöver resultatet vägas mot?
Underlaget omfattar endast utvalda artikelstycken; resultaten gäller en musmodell och några slutsatser om effekt hos människor kan inte dras.
Läs de originalstycken som sammanställningen bygger på
MethodsUtilizing myriocin, a potent inhibitor of sphingolipid synthesis, we evaluated the immune regulatory role of de novo ceramide generation in vitro and in vivo. Intratracheal myriocin was administered alone or during house dust mite sensitization (HDM) of BALB/C mice and airway hyper‐responsiveness (AHR) was evaluated by invasive plethysmography followed by bronchial lavage (BAL) cytology and cytokine quantification.
ResultsMyriocin inhibits and HDM exposure activates de novo ceramide synthesis in bone marrow‐derived dendritic cells. Mice receiving intratracheal myriocin developed a mild airway neutrophilic infiltrate without inducing a significant increase in AHR. CXCL1 was elevated in the BAL fluid of myriocin‐treated mice while the neutrophilic chemotactic factors anaphylatoxin C5a, leukotriene B4, and IL‐17 were unaffected. HDM treatment combined with myriocin led to a dramatic enhancement of AHR (63% increase over HDM alone, p < 0.001) and increased granulocyte pulmonary infiltrates versus HDM or myriocin alone. Elevated Th2 T cell counts and Th2 cytokines/chemokines (IL5, IL13, CCL17) were observed in mice treated with combined HDM/myriocin compared to HDM alone. Myriocin‐treated pulmonary CD11c+ cells stimulated with HDM secreted significantly more CXCL1 than cells stimulated with HDM alone while HDM stimulated airway epithelial cells showed no change in CXCL1 secretion following myriocin treatment.
Animals, immunizations, and materialsSeven‐ to eight‐week‐old BALB/c mice were purchased from Jackson Laboratory (Bar Harbor, ME), maintained in a specific pathogen free facility at Cincinnati Children's Hospital Medical Center (CCHMC) and handled under Institutional Animal Care and Use Committee‐approved procedures. Following isoflourane anesthesia, animals underwent allergen immunization as previously described with the following modifications: mice were serially immunized intratracheally every 48 h for 2 weeks with low‐endotoxin, low‐dose HDM extract (D. pteronyssinus, Greer Labs; Lenoir, NC) (3 μg total protein/dose in 50 μL of sterile phosphate‐buffered saline plus vehicle [PBS]). Myriocin (Cayman Chemical Company; Ann Arbor, MI) stock solutions (5 mM) were prepared in methanol, and aqueous solutions were prepared fresh before each experiment (1.2 μg/intratracheal dose). Ceramide C6 (N‐hexanoyl‐D‐erythro‐sphingosine) was obtained from Avanti Polar Lipids (Alabaster, AL), mouse GM‐CSF was acquired from PeproTech(Rocky Hill, NJ), and RPMI and serine‐free MEM were purchased from Gibco (Carsbad, CA). Normal human bronchial epithelial cells (NHBE) were obtained from Lonza (Walkerville, MD) and cultured per the manufacturer's instructions. Murine bone marrow‐derived dendritic cells (BMDCs) were generated as previously described .
Pulmonary SPT inhibition enhances airway hyper‐responsivenessAllergen‐induced AHR is a robust physiologic end‐point for quantitating the influence of bioactive compounds on the pathophysiology of allergic asthma. Using a well‐characterized murine model of HDM‐induced AHR, we investigated the biochemical and physiologic effects of intratracheal myriocin on lung lipid content, lung function, and airway structure (treatment protocol outlined in Fig. A). Similar to other investigators, we administered a low dose of intratracheal HDM extract, which sub‐maximally induces AHR and airway inflammation, thus increasing our ability to detect additive and synergistic effects , , , . First, we performed AHR measurement on mice after eight serial doses of intratracheal myriocin and did not detect a significant rise in AHR compared with vehicle‐treated control mice (Fig. B) despite a sustained reduction in lung ceramide levels (Fig. C). Next, we performed histologic examination of lung tissue from myriocin‐treated mice, which showed normal bronchial and alveolar architecture, similar to vehicle‐treated mice (Fig. A vs. D).
Pulmonary SPT inhibition enhances airway hyper‐responsivenessAfter establishing that intratracheal myriocin does not induce significant AHR in our system, we compared the effect of HDM/myriocin co‐administration with that of HDM alone and found that co‐administration significantly enhanced AHR (p < 0.001) (Fig. B). Myriocin's effect on lung ceramide levels, however, was undetectable in animals co‐treated with HDM/myriocin (Fig. C,Supplemental Fig. S1B). Lung histology from both HDM only and HDM/myriocin‐treated mice revealed similar levels of peribronchial inflammatory infiltrates (Fig. B vs. E) and goblet cell metaplasia (Fig. C vs. F, Supplementary Fig. S1C). Goblet cell gene expression analysis revealed that HDM exposure induced multiple asthma‐associated transcripts, including chloride channel calcium‐activated 1 (Clca1/Gob‐5), mucin 5, subtypes A and C, tracheobronchial/gastric (Muc5ac), intelectin 1 (Itln1), and intelectin 2 (Itln2/B). Compared to HDM alone, HDM/myriocin co‐administration enhanced Itln1 and Itln2 expression, had no effect on Clca1, and significantly decreased Muc5ac expression. Therefore, in an allergic model of asthma, myriocin‐treatment is associated with enhanced HDM‐induced AHR and an altered goblet cell gene expression pattern.
Artikelns licens · ActiQs sammanfattningar och texturval är bearbetningar av källan.
Myriocin-induced adaptive laboratory evolution of an industrial strain of Saccharomyces cerevisiae reveals its potential to remodel lipid composition and heat tolerance. ↗
Randez-Gil F, Prieto JA, Rodríguez-Puchades A, Casas J, Sentandreu V, Estruch F.
Vad undersöktes?
- Hur undersöktes det?
- adaptive laboratory evolution (ALE)
- Vilka undersöktes?
- an industrial yeast strain (LH) of Saccharomyces cerevisiae
- Vilken ämnesform?
- myriocin
- Vilken mängd användes?
- 1.2 μM myriocin
- Hur länge pågick studien?
- during 50 generations
Studieuppgifterna återges som originalcitat. Uppgifter som saknas här kan finnas i originalutdraget.
Vad kom studien fram till?
Författarna rapporterar att en industriell jäststam av Saccharomyces cerevisiae som evolverades i myriocins närvaro utvecklade tolerans mot myriocin och uppvisade förändringar i lipidprofilen; den evolverade populationen växte bättre vid 40°C än ursprungsstammen, medan tillväxten vid 30°C var opåverkad och tillväxten under kalla förhållanden försämrades.
Vad behöver resultatet vägas mot?
Underlaget omfattar endast utvalda artikelstycken; någon samlad bedömning kan inte göras.
Läs de originalstycken som sammanställningen bygger på
AbstractThe modification of lipid composition allows cells to adjust membrane biophysical properties in response to changes in environmental temperature. Here, we use adaptive laboratory evolution (ALE) in the presence of myriocin, a sphingolipid (SLs) biosynthesis inhibitor, to remodel the lipid profile of an industrial yeast strain (LH) of Saccharomyces cerevisiae. The approach enabled to obtain a heterogeneous population (LHev) of myriocin‐tolerant evolved clones characterized by its growth capacity at high temperature. Myriocin exposure also caused tolerance to soraphen A, an inhibitor of the acetyl‐CoA carboxylase Acc1, the rate‐limiting enzyme in fatty acid de novo production, supporting a change in lipid metabolism during ALE. In line with this, characterization of two randomly selected clones, LH03 and LH09, showed the presence of lipids with increased saturation degree and reduced acyl length. In addition, the clone LH03, which displays the greater improvement in fitness at 40°C, exhibited higher SL content as compared with the parental strain. Analysis of the LH03 and LH09 genomes revealed a loss of chromosomes affecting genes that have a role in fatty acid synthesis and elongation. The link between ploidy level and growth at high temperature was further supported by the analysis of a fully isogenic set of yeast strains with ploidy between 1N and 4N which showed that the loss of genome content provides heat tolerance. Consistent with this, a thermotolerant evolved population (LH40°) generated from the parental LH strain by heat‐driven ALE exhibited a reduction in the chromosome copy number. Thus, our results identify myriocin‐driven evolution as a powerful approach to investigate the mechanisms of acquired thermotolerance and to generate improved strains.
Adaptive evolution in the presence of myriocinWe used a robust industrial baker's yeast strain named L'Hirondelle (LH) in order to force by ALE changes in the lipid metabolism. For this, yeast was propagated by successive batch refreshments maintained constantly in the presence of myriocin at 30°C during 50 generations (see Fig. A). In these experiments, a chronic‐medium dose of 1.2 μM myriocin was used to lower but not completely inhibit SPT activity (Huang et al., ; Fig. B). Moreover, a short‐term experiment was chosen because deleterious mutations, which could affect negatively important traits of industrial strains, such as cell size, fitness or carbon‐source utilization (Aguilera et al., ; Wenger et al., ; Çakar et al., ; Strucko et al., ), have been reported to accumulate over time (Tenaillon et al., ). In general, the rates of spontaneous mutation are higher for neutral and deleterious mutations and lower for beneficial mutations (Barrick and Lenski, ; Van den Bergh et al., ). In this manner, we seek to generate evolved clones containing stable compensatory mutations conferring increased SL biosynthesis (see Fig. B) or altered PL asymmetry, but still maintaining key industrial properties. We found that the doubling time decreased gradually over the course of the experiment (data not shown), indicating that the original yeast population was capable of adapting to optimize growth in the presence of the drug. As shown in Fig. C, the 50‐generations evolved population (LHev) grew in a solid myriocin‐containing YPD medium, while the parental strain did not. As expected, tolerance to myriocin was also observed for 10 individual adaptive clones isolated from the terminal population. In addition, all of them showed a similar growth (Fig. C), suggesting that adaptation‐driving mutations were distributed across the population (Tenaillon et al., ).
Myriocin‐driven evolution alters yeast growth at different temperaturesWe asked whether the changes in myriocin tolerance observed in the evolved population were relevant for the physiological response to thermal stress. As shown in Fig. , growth at 30°C, the optimal temperature for S. cerevisiae of the yeast population was unaffected by the evolutionary experiment. On the contrary, the terminal population exhibited increased growth at 40°C as compared with the parental, whereas a trade‐off in cell proliferation under cold conditions was observed (Fig. ). Likewise, most of the selected clones under study (LH01–LH10) exhibited increased fitness at 40°C (data not shown) although again the phenotype differed quantitatively among individuals as it is illustrated for two randomly selected clones, LH03 and LH09 (Fig. ). Thus, the clone LH09 exhibited only a slight growth advantage at 40°C, as compared with the parental LH strain, while the LH03 clone grew much faster and had a similar behaviour to that of the LHev population. Finally, these phenotypes correlated again with a loss in cold growth (Fig. ). We conclude that myriocin‐drive evolution improved yeasts' ability to adapt to increased temperature with no apparent trade‐offs at the ancestral optimal temperature of 30°C. The results also highlight how tolerance to high temperature is associated with fitness impairments under cold‐stressful conditions.
Artikelns licens · ActiQs sammanfattningar och texturval är bearbetningar av källan.
Företagsuppgifter och hälsopåståenden · genomgång saknas ännu
Vi har ännu ingen källbunden genomgång av företagens påståenden för den här formen.
Ett företags beskrivning behöver läsas som företagets uppgift. För att bedöma stödet behöver man även se originalstudierna, den undersökta ämnesformen och resultatens begränsningar.
Begränsningar och försiktighetsuppgifter · genomgång saknas ännu
Grundbeskrivningen förklarar ämnet. Den bedömer inte nytta eller säkerhet vid användning av ett tillskott. Studieresultat för ett salt, en jon eller en annan form kan inte automatiskt överföras till den här formen.
En genomgång av källbelagda försiktighetsuppgifter saknas ännu. Sidan ger därför ingen samlad säkerhetsbedömning eller råd om dosering och behandling.
Kemisk fördjupning · fler namn, identifierare och källuppgifter
Kemiska källuppgifter
- Molekylformel
- C21H39NO6
- Laddning
- 0
- Molekylmassa
- 401.544
- InChIKey
- ZZIKIHCNFWXKDY-GNTQXERDSA-N
- SMILES
- CCCCCCC(=O)CCCCCC/C=C/C[C@@H](O)[C@H](O)[C@@](N)(CO)C(=O)O
- Källans klassificering
- 3:STAR
Synonymer
EXACT är källans exakta synonym. RELATED, BROAD och NARROW kan vara relaterade, bredare eller snävare benämningar. Sådana namn innebär inte automatiskt samma identitet.
- (2S,3R,4R)-(E)-2-amino-3,4-dihydroxy-2-hydroxymethyl-14-oxoeicos-6-enoic acid RELATED
- (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid RELATED
- (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid EXACT
- (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid RELATED
- ISP-1 RELATED
- ISP-I RELATED
- antibiotic ISP-1 RELATED
- antibiotic ISP-I RELATED
- thermozymocidin RELATED
Definition
An amino acid-based antibiotic derived from certain thermophilic fungi; acts as a potent inhibitor of serine palmitoyltransferase, the first step in sphingosine biosynthesis. Myriocin also possesses immunosuppressant activity.
Källans text; inga egna slutsatser har lagts till.Identifierare i källan
- agr: IND607305181
- cas: 35891-70-4
- kegg.compound: C19914
- knapsack: C00016936
- lipidmaps: LMFA01060203
- pdb-ccd: VRP
- pubmed: 15679316
- pubmed: 21456524
- pubmed: 23178537
- pubmed: 23659342
- pubmed: 23802886
- pubmed: 23957439
- pubmed: 24141140
- pubmed: 24395529
- pubmed: 24456332
- pubmed: 27621809
- pubmed: 28621883
- pubmed: 30123648
- pubmed: 30883241
- pubmed: 31447688
- pubmed: 31639005
- pubmed: 31701696
- pubmed: 32091078
- pubmed: 32212314
- pubmed: 32435178
- pubmed: 32954686
- pubmed: 33378044
- pubmed: 33441497
- pubmed: 33482299
- pubmed: 33558761
- pubmed: 33731109
- pubmed: 34324668
- pubmed: 4694226
- pubmed: 5076310
- pubmed: 8020136
- reaxys: 5113331
- wikipedia.en: Myriocin
Relationer och ämnesformer
- RO:0000087 · antimicrobial agent
- RO:0000087 · antineoplastic agent
- RO:0000087 · immunosuppressive agent
- RO:0000087 · antifungal agent
- RO:0000087 · EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
- RO:0000087 · apoptosis inducer
- RO:0000087 · fungal metabolite
- is_a · sphingoid
- is_a · hydroxy monocarboxylic acid
- is_a · alpha-amino fatty acid
- is_a · non-proteinogenic alpha-amino acid
Besläktade ämnen och beståndsdelar
Följ hur ämnet hänger ihop med andra kemiska identiteter.
Fördjupning · ämnesklasser och roller
- antimicrobial agent
Har källklassificerad roll
Kopplingens underlag
myriocin → antimicrobial agent
Originalregister
RO:0000087 · 1e8d2a96-b5a4-4c85-ad85-ec725354df4b - antineoplastic agent
Har källklassificerad roll
Kopplingens underlag
myriocin → antineoplastic agent
Originalregister
RO:0000087 · 1e8d2a96-b5a4-4c85-ad85-ec725354df4b - immunosuppressive agent
Har källklassificerad roll
Kopplingens underlag
myriocin → immunosuppressive agent
Originalregister
RO:0000087 · 1e8d2a96-b5a4-4c85-ad85-ec725354df4b - antifungal agent
Har källklassificerad roll
Kopplingens underlag
myriocin → antifungal agent
Originalregister
RO:0000087 · 1e8d2a96-b5a4-4c85-ad85-ec725354df4b - sphingoid
Tillhör ämnesklassen
- hydroxy monocarboxylic acid
Tillhör ämnesklassen
Kopplingens underlag
myriocin → hydroxy monocarboxylic acid
Originalregister
is_a · 1e8d2a96-b5a4-4c85-ad85-ec725354df4b - EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
Har källklassificerad roll
Kopplingens underlag
myriocin → EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
Originalregister
RO:0000087 · 1e8d2a96-b5a4-4c85-ad85-ec725354df4b - alpha-amino fatty acid
Tillhör ämnesklassen
Kopplingens underlag
myriocin → alpha-amino fatty acid
Originalregister
is_a · 1e8d2a96-b5a4-4c85-ad85-ec725354df4b - apoptosis inducer
Har källklassificerad roll
Kopplingens underlag
myriocin → apoptosis inducer
Originalregister
RO:0000087 · 1e8d2a96-b5a4-4c85-ad85-ec725354df4b - fungal metabolite
Har källklassificerad roll
Kopplingens underlag
myriocin → fungal metabolite
Originalregister
RO:0000087 · 1e8d2a96-b5a4-4c85-ad85-ec725354df4b - non-proteinogenic alpha-amino acid
Tillhör ämnesklassen
Kopplingens underlag
myriocin → non-proteinogenic alpha-amino acid
Originalregister
is_a · 1e8d2a96-b5a4-4c85-ad85-ec725354df4b
Relationer beskriver källans kemiska struktur eller klassificering. Ämnena behåller separata identiteter. Detta innebär inte samma innehåll, dosering, effekt eller säkerhet.
Utforska ingrediensens kopplingar
Följ länkarna till produkter, publikationer och källuppgifter för just den här formen.
Se kopplingarna i ett diagram →Publikationer i källan
ChEBI hänvisar till 29 PubMed-publikationer för den här posten. Kopplingen är en källhänvisning och innebär ingen egen slutsats om effekt eller säkerhet.
29 publikationsposter har hämtats hittills. Registret fylls automatiskt.
Effects of serine palmitoyltransferase inhibition by myriocin in ad libitum-fed and nutrient-restricted ewes.
Davis AN, Myers WA, Eduardo Rico J, Feng Wang L, Chang C, Richards AT, Moniruzzaman M, Haughey NJ, McFadden JW.
J Anim Sci · research-article; journal article · DOI 10.1093/jas/skab221Comprehensive transcriptomic and proteomic analyses identify intracellular targets for myriocin to induce Fusarium oxysporum f. sp. niveum cell death.
Wang H, Wang Z, Xu W, Wang K.
Microb Cell Fact · research-article; journal article · DOI 10.1186/s12934-021-01560-zStructural insights into the regulation of human serine palmitoyltransferase complexes.
Wang Y, Niu Y, Zhang Z, Gable K, Gupta SD, Somashekarappa N, Han G, Zhao H, Myasnikov AG, Kalathur RC, Dunn TM, Lee CH.
Nat Struct Mol Biol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41594-020-00551-9Myriocin modulates the altered lipid metabolism and storage in cystic fibrosis.
Signorelli P, Pivari F, Barcella M, Merelli I, Zulueta A, Dei Cas M, Rosso L, Ghidoni R, Caretti A, Paroni R, Mingione A.
Cell Signal · research support, non-u.s. gov't; journal article · DOI 10.1016/j.cellsig.2021.109928Study on the Inhibitory Activity and Possible Mechanism of Myriocin on Clinically Relevant Drug-Resistant Candida albicans and Its Biofilms.
Yang X, Pei Z, Hu R, Zhang Z, Lou Z, Sun X.
Biol Pharm Bull · journal article · DOI 10.1248/bpb.b20-00246Jämför med en annan ingrediens →
Produkter som deklarerar den här formen
Här finns produkter som har kopplats till just den här formen. Saknade träffar betyder inte att formen saknas i alla produkter.
Ämnet i källregistren
Utforska ingredienslistor och EU-register med tillgängliga kopplingar till detta ämne.
Visa källposter för ämnet →Källversioner
ChEBI 255 ·
ChEBI · EMBL-EBI · CC BY 4.0 · CC BY 4.0
Öppna originalkällan →